Literature DB >> 12605205

British anti-Lewisite (dimercaprol): an amazing history.

Joel A Vilensky1, Kent Redman.   

Abstract

Emergency physicians are familiar with British anti-Lewisite (BAL) because it is a heavy metal-chelating agent that is recommended in some cases of metal poisoning, especially arsenic. Although there are more modern chelating agents, the fact that BAL is still recommended and stocked by hospital pharmacies more than 60 years after its initial synthesis is itself remarkable. During World War II, BAL minimized the risk to the Allied infantry of injury or death from Lewisite, a very potent arsenic-based chemical warfare agent. Once developed, BAL revolutionized the treatment of heavy metal poisonings, both accidental and iatrogenic (eg, toxicity from treatment of arthritis with gold salts). In 1951, BAL was used to treat Wilson's disease with striking success. Today, BAL might again become prominent should terrorists or governments use Lewisite against civilians or military forces.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12605205     DOI: 10.1067/mem.2003.72

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  12 in total

1.  Dilated cardiomyopathy and left bundle branch block associated with ingestion of colloidal gold and silver is reversed by British antiLewisite and vitamin E: the potential toxicity of metals used as health supplements.

Authors:  Stephen Lawrence Archer
Journal:  Can J Cardiol       Date:  2008-05       Impact factor: 5.223

2.  The catecholaminergic neurotransmitter system in methylmercury-induced neurotoxicity.

Authors:  Marcelo Farina; Michael Aschner; João Batista Teixeira da Rocha
Journal:  Adv Neurotoxicol       Date:  2017-09-01

3.  Post-translational Activation of Glutamate Cysteine Ligase with Dimercaprol: A NOVEL MECHANISM OF INHIBITING NEUROINFLAMMATION IN VITRO.

Authors:  Pallavi B McElroy; Ashwini Sri Hari; Brian J Day; Manisha Patel
Journal:  J Biol Chem       Date:  2017-02-15       Impact factor: 5.157

4.  Molecular Mechanism Underlying Pathogenesis of Lewisite-Induced Cutaneous Blistering and Inflammation: Chemical Chaperones as Potential Novel Antidotes.

Authors:  Changzhao Li; Ritesh K Srivastava; Zhiping Weng; Claire R Croutch; Anupam Agarwal; Craig A Elmets; Farrukh Afaq; Mohammad Athar
Journal:  Am J Pathol       Date:  2016-08-12       Impact factor: 4.307

5.  Systematic identification of arsenic-binding proteins reveals that hexokinase-2 is inhibited by arsenic.

Authors:  Hai-Nan Zhang; Lina Yang; Jian-Ya Ling; Daniel M Czajkowsky; Jing-Fang Wang; Xiao-Wei Zhang; Yi-Ming Zhou; Feng Ge; Ming-Kun Yang; Qian Xiong; Shu-Juan Guo; Huang-Ying Le; Song-Fang Wu; Wei Yan; Bingya Liu; Heng Zhu; Zhu Chen; Sheng-Ce Tao
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-23       Impact factor: 11.205

Review 6.  A TACTful reappraisal of chelation therapy in cardiovascular disease.

Authors:  Mandeep S Sidhu; Basil M Saour; William E Boden
Journal:  Nat Rev Cardiol       Date:  2013-12-17       Impact factor: 32.419

7.  Histopathological and Molecular Changes in the Rabbit Cornea From Arsenical Vesicant Lewisite Exposure.

Authors:  Neera Tewari-Singh; Dinesh G Goswami; Rama Kant; David A Ammar; Dileep Kumar; Robert W Enzenauer; Robert P Casillas; Claire R Croutch; J Mark Petrash; Rajesh Agarwal
Journal:  Toxicol Sci       Date:  2017-12-01       Impact factor: 4.849

8.  Identification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugs.

Authors:  Min Shen; Yaqin Zhang; Nakhle Saba; Christopher P Austin; Adrian Wiestner; Douglas S Auld
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

Review 9.  Cadmium toxicity and treatment: An update.

Authors:  Mehrdad Rafati Rahimzadeh; Mehravar Rafati Rahimzadeh; Sohrab Kazemi; Ali-Akbar Moghadamnia
Journal:  Caspian J Intern Med       Date:  2017

Review 10.  Current approaches of the management of mercury poisoning: need of the hour.

Authors:  Mehrdad Rafati-Rahimzadeh; Mehravar Rafati-Rahimzadeh; Sohrab Kazemi; Ali Akbar Moghadamnia
Journal:  Daru       Date:  2014-06-02       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.